Original document(7 pages)  中文版
    The present invention discloses aspirin buccal tablet and its preparation process, and the aspirin buccal tablet consists of aspirin, diluent, adhesive, pH regulator, corrective and lubricant. The aspirin buccal tablet has new administration mode and is used in preventing heart diseases and cerebral thrombosis. It is absorbed and dispersed by mucous membrane of mouth and has reduced stimulation on gastrointestinal tract. The preparation process has proper adhesive added for wet pelletizing, and pH regulator and compressible starch added to avoid hydrolysis of aspirin. The aspirin buccal tablet has proper mouth feeling for easy taking.
Application Number
申请号
200610107068 Application Date
申请日
2006.09.19
Title 名称 Aspirin buccal tablet and its prepn process
Publication Number
公开号
1931174 Publication Date
公开日
2007.03.21
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K31/616;A61K9/20;A61P29/00;A61P9/10;A61P7/02
Applicant(s) Name
申请人
Zhengzhou Sanchuang Medicine Release Techn Co., Ltd.
Address 地址
Inventor(s) Name 发明人
Attorney & Agent 代理人
More information 更  多  信  息


 Related patents information
Aspilrin slow release tablet
Composite tubular material with triangular cavity structure
Composite plate material with triangular cavity structure
Electronic purse terminal capable of replacing check code
CMOS device with longitudinal ring grating non-homogeneous germanium silicon doped channel
Strained Si channel PMOS device
Floated in staomach type slow-release tablets contg. berberine hydrochloide and its prepn. method
Cool tea buccal tablets and its preparation method
Antialcoholism quick lozenge and preparation process thereof
Cosmetic product for treating acne
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.